
Shattuck Labs (STTK) Stock Forecast & Price Target
Shattuck Labs (STTK) Analyst Ratings
Bulls say
Shattuck Labs Inc. is strategically positioned in the biotechnology sector, focusing on innovative treatments for inflammatory diseases, with a notable program, SL-325, aimed at becoming a first-in-class DR3 antagonist antibody. The significant increase in biologics usage among patients with Crohn's Disease (from 22% to 44%) and Ulcerative Colitis (from 5% to 16%) between 2007 and 2015 demonstrates a growing market opportunity, suggesting that demand for effective treatments is on the rise. Additionally, the company's conservative projections for SL-325's sales growth reflect a positive outlook for substantial market share growth, driven by the ongoing demand for high-efficacy and safe therapeutic options in this expanding segment.
Bears say
Shattuck Labs Inc faces significant challenges in its development of therapies for inflammatory bowel disease (IBD), as evidenced by market growth and advanced therapy adoption being consistently underestimated since the launch of the first biologics. The company’s lead programs, including SL-325 and SL-425, carry inherent risks, such as potential ineffectiveness, high immunogenicity, or negative safety signals, which could impede their development and market adoption. Additionally, the reliance on clinical response metrics, such as the Crohn's Disease Activity Index (CDAI), further complicates the outcome predictions, contributing to uncertainty regarding the future viability of its product pipeline and overall financial outlook.
This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.
Shattuck Labs (STTK) Analyst Forecast & Price Prediction
Start investing in Shattuck Labs (STTK)
Order type
Buy in
Order amount
Est. shares
0 shares